Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, VISEN Pharmaceuticals's Enterprise Value is €206.81 Mil.
VISEN Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €-29.37 Mil. Therefore, VISEN Pharmaceuticals's EV-to-EBIT ratio for today is -7.04.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, VISEN Pharmaceuticals's Enterprise Value is €206.81 Mil.
VISEN Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €-28.92 Mil. Therefore, VISEN Pharmaceuticals's EV-to-EBITDA ratio for today is -7.15.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
VISEN Pharmaceuticals (FRA:T06) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
VISEN Pharmaceuticals's current Enterprise Value is €206.81 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. VISEN Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €-29.37 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
VISEN Pharmaceuticals's EV-to-EBITDA for today is:
VISEN Pharmaceuticals's current Enterprise Value is €206.81 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. VISEN Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €-28.92 Mil.
VISEN Pharmaceuticals's current Enterprise Value is €206.81 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. VISEN Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 was €4.45 Mil.
VISEN Pharmaceuticals's current Enterprise Value is €206.81 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. VISEN Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €-56.36 Mil.
VISEN Pharmaceuticals's current Enterprise Value is €206.81 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. VISEN Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was €-56.43 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VISEN Pharmaceuticals Enterprise Value Related Terms
VISEN Pharmaceuticals Enterprise Value Historical Data
* Premium members only.
The historical data trend for VISEN Pharmaceuticals's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, VISEN Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VISEN Pharmaceuticals Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, VISEN Pharmaceuticals's Enterprise Value distribution charts can be found below:
* The bar in red indicates where VISEN Pharmaceuticals's Enterprise Value falls into.
VISEN Pharmaceuticals Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
VISEN Pharmaceuticals's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VISEN Pharmaceuticals (FRA:T06) has a Enterprise Value of €206.81 Mil as of Aug. 29, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on VISEN Pharmaceuticals and its competitors.
Is VISEN Pharmaceuticals' Enterprise Value too high?
VISEN Pharmaceuticals' current Enterprise Value is €206.81 Mil. Overall, VISEN Pharmaceuticals has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does VISEN Pharmaceuticals' Enterprise Value compare to ZTS?
VISEN Pharmaceuticals' Enterprise Value of €206.81 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on VISEN Pharmaceuticals and its competitors. VISEN Pharmaceuticals's current Enterprise Value is €206.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VISEN Pharmaceuticals stock overvalued right now?
VISEN Pharmaceuticals (FRA:T06) has a current Enterprise Value of €206.81 Mil. The current Enterprise Value is €206.81 Mil. VISEN Pharmaceuticals' overall GF Score™ is 7/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For VISEN Pharmaceuticals (FRA:T06), the current Enterprise Value is €206.81 Mil as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
VISEN Pharmaceuticals is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China. It has one Core Product and two other pipeline drug candidates. Its Core Product, lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency (PGHD), a common short stature in patients aged under 18 caused by insufficient growth hormone. TransCon CNP (navepegritide), one of its key drug candidates, is a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia (ACH), a short-limbed dwarfism that results in severe skeletal complications and comorbidities.
7GF Score
Get the complete analysis for FRA:T06
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:T06 has been successfully added to your 
